Trillium Therapeutics’ (TR) Market Perform Rating Reaffirmed at Leerink Swann

Leerink Swann reiterated their market perform rating on shares of Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) in a research note published on Friday morning.

TR stock opened at C$30.20 on Friday. Trillium Therapeutics has a 12 month low of C$28.50 and a 12 month high of C$39.45.

How to Become a New Pot Stock Millionaire

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) last released its quarterly earnings data on Friday, March 9th. The company reported C($0.91) EPS for the quarter, beating the consensus estimate of C($1.06) by C$0.15.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/trillium-therapeutics-tr-market-perform-rating-reaffirmed-at-leerink-swann-2.html.

About Trillium Therapeutics

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply